Biomedical Reform Legislation Draft Could Be Released By January
This article was originally published in The Pink Sheet Daily
Executive Summary
At the final roundtable for the 21st Century Cures initiative in Washington, Chairman Upton promises swift action, and urges stakeholders to submit their ideas “as soon as possible.”
You may also be interested in...
Waxman’s Congressional Exclusivity Set To Expire, But There Will Be No Equivalents
Retiring after 40 years in Congress, Waxman leaves an enormous legacy, but also many recent legislative defeats.
Antibiotics Legislation Could Boost Confidence Of Sponsors And FDA Alike
A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.
Pink Sheet Podcast: Finally, A US FDA User Fee Deal, ‘Pandemic Is Over’ Take-Aways, Tpoxx Development Issues
Pink Sheet reporters and editor discuss the impact of the long wait for a user fee deal to be negotiated, how the FDA will interpret President Biden’s statement that the COVID-19 pandemic is over, and concerns with the clinical development of the monkeypox treatment Tpoxx.